Latest Bambusa Therapeutics News & Updates

See the latest news and media coverage for Bambusa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Bambusa Therapeutics (Bambusa)

Clinical-stage biotechnology company

bambusatx.com

Headquarters: BOSTON, United States
Founded year: 2024
Company type: Private company
Number of employees: 20–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Bambusa Therapeutics (Bambusa)

In short: Bambusa achieved positive preliminary results for its lead bispecific antibody BBT001 in atopic dermatitis and advanced BBT002 trials.

Company announcements

July 28 Bambusa

Bambusa reports positive results for BBT001 in atopic dermatitis

BBT001 showed statistically significant improvement in EASI and early itch relief with favorable safety and extended half-life.

June 15 Bambusa

Bambusa announces positive Phase 1 data for BBT002

The bispecific antibody targets IL-4Rα and IL-5, showing sustained biomarker effects for 8 weeks.

May 18 Bambusa

Bambusa reports positive Phase 1 data and begins new trial

The antibody showed depletion of eosinophils, and the Phase 1b/2a trial is for chronic rhinosinusitis with nasal polyps.

May 1 Bambusa

Bambusa completes enrollment in BBT001 trial

The Phase 1b/2a trial targets moderate-to-severe atopic dermatitis. Topline results are expected in mid-2026.

Media coverage

July 27 Yahoo Finance

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

Bambusa Therapeutics, Inc. (Bambusa Therapeutics or Bambusa), a clinical-stage biotechnology company developing next-generation, long-acting bispecific antibodies designed for immunology and inflammation (I&I...

June 15 Yahoo Finance

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced ...

May 18 Yahoo Finance

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced the presentation of preliminary data...

April 30 The Manila Times

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of...

Never miss news about Bambusa

Track Bambusa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Bambusa competitors & trending companies

Browse news for competitors to Bambusa and other trending companies.